Dr Sumathi Kanniappan

Dr. Sumathi Kanniappan is a senior Consultant Endocrinologist at Rainbow Children’s Hospital, Hebbal, Bengaluru, with over 20 years of experience. She specializes in preventive medicine, cardiovascular health, diabetes management, gestational diabetes, women’s health, obesity, hormonal imbalances, and endocrine disorders of the pituitary, thyroid, adrenal, and gonadal glands. Dr. Sumathi has actively participated in international clinical research programs and conferences and brings evidence-based, holistic care to her patients.

Educational Qualifications:

• MBBS – Bangalore University
• FEDM – Fellow, Endocrinology & Diabetes Management
• FACE – Fellow, American College of Endocrinology

Professional Experience:

• Consultant Endocrinologist, Rainbow Children’s Hospital, Hebbal, Bengaluru
• Visiting Clinician Programme, Department of Endocrinology, Mayo Clinic, Rochester, USA
• Active participant in international clinical research trials on diabetes management
• Extensive experience in managing women and pediatric diabetes, gestational diabetes, hormonal disorders, obesity, and metabolic syndromes

International Conferences & Clinical Research:

• Visiting Clinician Programme, Department of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA
• AACE 24th Annual Scientific and Clinical Congress, Nashville, Tennessee, USA
• ADA 75th Scientific Sessions, Boston, MA, USA
• Asia-Pacific Pediatric Endocrinology Society (APPES) Scientific Conference, Bali, Indonesia, 2012
• Asia Oceania Thyroid Association Congress, Kochi, India, 2014
• Attended International Clinical Research Meeting, London, UK, conducted by Novartis, 2009
• Participated in a multi-center, double-blind, placebo-controlled randomized trial on Canakinumab in patients with impaired glucose tolerance or Type 2 diabetes, 2009
• Attended International Clinical Research Meeting, Prague, Czechoslovakia, 2010
• Participated in SAVOR-TIMI Trial (Saxagliptin) – Phase IV randomized, double-blind, placebo-controlled study evaluating cardiovascular outcomes in Type 2 Diabetes, Prague, 2010
• Attended International Clinical Research Meeting, Singapore City, 2010
• Participated in multicenter, randomized, double-blind, placebo and active-controlled trial evaluating Canagliflozin (JNJ-28431754) vs Sitagliptin and placebo in Type 2 Diabetes patients with inadequate glycemic control on Metformin Monotherapy.

‍